Arcturus Therapeutics Reports Phase 1b Data for Cystic Fibrosis Treatment
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics (NASDAQ: ARCT) announced positive interim Phase 1b data for its cystic fibrosis treatment, ARCT-032. The data showed an average improvement of 4% FEV1 in the first four CF patients after two administrations. The company will present these findings at the European Cystic Fibrosis Conference on June 7, 2024.
May 28, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics reported positive interim Phase 1b data for its cystic fibrosis treatment, ARCT-032, showing a 4% improvement in FEV1 in the first four patients. The full results will be presented at the European Cystic Fibrosis Conference on June 7, 2024.
The positive interim data for ARCT-032 indicates potential efficacy in treating cystic fibrosis, which could boost investor confidence and positively impact ARCT's stock price in the short term. The upcoming presentation at a major conference further adds to the potential positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100